The synergetic interaction of these two PD medicaments caused a suppressive effect on gene expressions of synuclein alpha (SNCA, as a ubiquitously expressed protein affecting the regulation of dopamine release) and Leucine-rich repeat kinase 2 (LRRK2), as an enzyme containing kinase and GTPase function, which its mutation is the most frequent genetic cause of PD. The gene discussed is SNCA; the disease is Parkinson disease.